Jazz Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Jazz Pharmaceuticals has a total shareholder equity of $3.7B and total debt of $5.7B, which brings its debt-to-equity ratio to 153%. Its total assets and total liabilities are $11.4B and $7.7B respectively. Jazz Pharmaceuticals's EBIT is $810.7M making its interest coverage ratio 2.8. It has cash and short-term investments of $1.6B.
Key information
153.0%
Debt to equity ratio
US$5.72b
Debt
| Interest coverage ratio | 2.8x |
| Cash | US$1.63b |
| Equity | US$3.74b |
| Total liabilities | US$7.66b |
| Total assets | US$11.39b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: JAZZ N's short term assets ($3.4B) exceed its short term liabilities ($1.5B).
Long Term Liabilities: JAZZ N's short term assets ($3.4B) do not cover its long term liabilities ($6.1B).
Debt to Equity History and Analysis
Debt Level: JAZZ N's net debt to equity ratio (109.3%) is considered high.
Reducing Debt: JAZZ N's debt to equity ratio has increased from 57.9% to 153% over the past 5 years.
Debt Coverage: JAZZ N's debt is not well covered by operating cash flow (19.1%).
Interest Coverage: JAZZ N's interest payments on its debt are not well covered by EBIT (2.8x coverage).